MA47499A - Anticorps anti-tau et leurs procédés d'utilisation - Google Patents

Anticorps anti-tau et leurs procédés d'utilisation

Info

Publication number
MA47499A
MA47499A MA047499A MA47499A MA47499A MA 47499 A MA47499 A MA 47499A MA 047499 A MA047499 A MA 047499A MA 47499 A MA47499 A MA 47499A MA 47499 A MA47499 A MA 47499A
Authority
MA
Morocco
Prior art keywords
tau
bodies
methods
tau bodies
Prior art date
Application number
MA047499A
Other languages
English (en)
Inventor
Xiaocheng Chen
Mark S Dennis
Lesley Ann Kane
Do Jin Kim
Joseph W Lewcock
Suresh Poda
Rishi Rakhit
Rinkan Shukla
Adam P Silverman
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MA47499A publication Critical patent/MA47499A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA047499A 2017-02-17 2018-02-15 Anticorps anti-tau et leurs procédés d'utilisation MA47499A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762460642P 2017-02-17 2017-02-17
US201762583400P 2017-11-08 2017-11-08

Publications (1)

Publication Number Publication Date
MA47499A true MA47499A (fr) 2019-12-25

Family

ID=61563475

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047499A MA47499A (fr) 2017-02-17 2018-02-15 Anticorps anti-tau et leurs procédés d'utilisation

Country Status (14)

Country Link
US (1) US11370832B2 (fr)
EP (1) EP3583123A1 (fr)
JP (1) JP2020508054A (fr)
KR (1) KR20190134997A (fr)
CN (1) CN110520440A (fr)
AU (1) AU2018221049A1 (fr)
BR (1) BR112019017021A2 (fr)
CA (1) CA3053379A1 (fr)
IL (1) IL268658A (fr)
MA (1) MA47499A (fr)
MX (1) MX2019009817A (fr)
SG (1) SG11201907422RA (fr)
TW (1) TW201843175A (fr)
WO (1) WO2018152359A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165271A2 (fr) 2013-03-13 2014-10-09 Neotope Biosciences Limited Immunothérapie contre tau
EP3452507B1 (fr) 2016-05-02 2022-10-19 Prothena Biosciences Limited Immunothérapie anti-tau
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
WO2019094576A1 (fr) * 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anticorps bispécifiques bace-tau
WO2019094608A1 (fr) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anticorps anti-bace1 et leurs procédés d'utilisation
BR112020013921A2 (pt) * 2018-01-10 2020-12-01 Denali Therapeutics Inc. polipeptídeos de ligação ao receptor de transferrina e usos destes
CA3109763A1 (fr) * 2018-08-16 2020-02-20 Denali Therapeutics Inc. Proteines bispecifiques modifiees
EP3840781A1 (fr) * 2018-08-22 2021-06-30 Denali Therapeutics Inc. Polypeptides anti-her2 et leurs méthodes d'utilisation
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
KR102905634B1 (ko) * 2019-05-31 2025-12-30 일라이 릴리 앤드 캄파니 인간 타우를 표적화하는 화합물 및 방법
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
EP4085251B1 (fr) 2020-01-02 2024-07-31 F. Hoffmann-La Roche AG Procédé pour déterminer la quantité d'un anticorps thérapeutique dans le cerveau
US11124567B2 (en) * 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
CA3200865A1 (fr) * 2020-09-29 2022-04-07 Innovent Biologics (Suzhou) Co., Ltd. Anticorps bispecifique anti-claudine 18.2 et cd3 et son utilisation
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
EP4405680A1 (fr) 2021-09-20 2024-07-31 Institut National de la Santé et de la Recherche Médicale (INSERM) Procédés pour l'amélioration de l'efficacité d'une thérapie par inhibiteur de hdac et la prédiction de la réponse à un traitement comprenant un inhibiteur de hdac
WO2024133723A1 (fr) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Méthodes permettant de diminuer la résistance thérapeutique acquise à la chimiothérapie et/ou à la radiothérapie
WO2025171285A1 (fr) * 2024-02-09 2025-08-14 University Of Notre Dame Du Lac Protéomimétiques tau

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE154642T1 (de) * 1991-10-25 1997-07-15 Innogenetics Nv Monoklonale antikörper gegen das mikrotubulusassoziierte protein tau.
DE60334460D1 (de) 2002-08-14 2010-11-18 Mitsubishi Chem Medience Corp Antikörper spezifisch für das tau-protein des zentralen nervensystems
WO2005062977A2 (fr) 2003-12-23 2005-07-14 The Regents Of The University Of California Anticorps humains d'internalisation specifiques du cancer de la prostate
WO2005113798A2 (fr) 2004-04-15 2005-12-01 University Of Florida Research Foundation, Inc. Marqueurs proteolytiques, biomarqueurs diagnostiques du cancer, et des lesions des organes et des lesions des muscles dues a un surentrainement lors de rehabilitations ou d'exercices
US7435804B2 (en) * 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b
MX2008011933A (es) 2006-03-21 2008-12-18 Wyeth Corp Metodos y composiciones para antagonismo de rage.
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
HUE033325T2 (en) 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
WO2011133919A1 (fr) 2010-04-22 2011-10-27 Janssen Alzheimer Immunotherapy Utilisation de tau pour un suivi d'immunothérapie
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
WO2010136508A2 (fr) 2009-05-28 2010-12-02 Glaxo Group Limited Ciblage de cellules souches
EP4218794A3 (fr) * 2009-06-10 2023-09-13 New York University Ciblage immunologique de protéines tau pathologiques
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US20170315136A9 (en) 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
EP2470211B1 (fr) 2009-08-28 2016-01-27 The Board of Regents of The University of Texas System Anticorps liant les oligomères de la protéine tau
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
AU2010291933B2 (en) 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
WO2012045882A2 (fr) 2010-10-07 2012-04-12 Ac Immune S.A. Composition pharmaceutique
LT2627672T (lt) 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
WO2012106363A2 (fr) * 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Traitement de tauopathies
WO2012162179A1 (fr) 2011-05-20 2012-11-29 Oligomerix, Inc. Compositions de protéase tau et procédés d'utilisation
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
EP3275461A1 (fr) 2011-09-19 2018-01-31 Axon Neuroscience SE Thérapie protéique et diagnostic d'une pathologie à médiation par tau dans la maladie d'alzheimer
JP6358953B2 (ja) 2011-10-07 2018-07-18 エーシー イミューン エス．エー． タウを認識するホスホ特異的抗体
CA2859665C (fr) 2011-12-20 2024-05-21 Janssen Biotech, Inc. Anticorps anti-phf-tau et leurs utilisations
CA2869438C (fr) 2012-04-05 2021-08-17 Ac Immune S.A. Anticorps tau humanise
TWI700296B (zh) 2012-05-31 2020-08-01 公立大學法人大阪市立大學 失智症治療劑或預防劑
EP2870176A4 (fr) * 2012-07-03 2016-09-28 Univ Washington Anticorps dirigés contre tau
EP2885010B1 (fr) 2012-08-16 2020-01-01 Ipierian, Inc. Méthodes de traitement d'une tauopathie
EP2906596B1 (fr) 2012-10-12 2023-12-27 Arizona Board of Regents on behalf of Arizona State University Réactifs à base d'anticorps qui reconnaissent spécifiquement des formes oligomériques toxiques de tau
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
JP6284548B2 (ja) 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
WO2014165271A2 (fr) 2013-03-13 2014-10-09 Neotope Biosciences Limited Immunothérapie contre tau
ES2835716T3 (es) 2013-03-15 2021-06-23 Beth Israel Deaconess Medical Ct Inc Procedimientos y composiciones para la generación y el uso de anticuerpos específicos de conformación
MX374811B (es) 2013-03-15 2025-03-06 Ac Immune Sa Anticuerpos anti-tau y métodos de uso.
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
EP3041865A2 (fr) 2013-09-03 2016-07-13 NovImmune S.A. Molécules de liaison bispécifiques facilement isolées au format natif, mais possédant des régions constantes mutées
BR112016010454A2 (pt) 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
JP2017505756A (ja) 2013-12-13 2017-02-23 ザ ジェネラル ホスピタル コーポレイション 可溶性高分子量（ｈｍｗ）タウ種およびその用途
CR20160270A (es) 2013-12-20 2016-09-05 Hoffmann La Roche ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
EP2899208A1 (fr) 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Anticorps à domaine unique de camélidés dirigés contre des protéines tau phosphorylées et procédés de production de conjugués de ceux-ci
EP3105251A4 (fr) 2014-02-10 2017-11-15 Merck Sharp & Dohme Corp. Anticorps qui se lient à la protéine tau humaine et dosage pour quantifier la protéine tau humaine au moyen des anticorps
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽，抗Tau抗体，及其使用方法
MX367600B (es) 2014-02-19 2019-08-28 Hoffmann La Roche Transportador de la barrera hematoencefálica.
CA2952741A1 (fr) 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Anticorps et fragments de liaison a l'antigene qui se lient specifiquement a la proteine tau associee aux microtubules
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
EP3166688B1 (fr) 2014-07-08 2024-08-21 New York University Ligands de visualisation de tau et leurs utilisations dans le diagnostic et le traitement de tauopathies
DE102014013571A1 (de) 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoklonaler Antikörper gegen humanes TAU-Protein
CA3001724A1 (fr) 2014-10-10 2016-04-14 National Research Council Of Canada Anticorps anti-tau et ses utilisations
US10323082B2 (en) 2014-10-14 2019-06-18 The Research Foundation For Mental Hygiene, Inc. Treatment of tauopathies by passive immunization targeting the N-terminal projection domain of tau
EP3221349B1 (fr) 2014-11-19 2020-11-04 Axon Neuroscience SE Anticorps anti-tau humanisés dans la maladie d'alzheimer
WO2016112078A2 (fr) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anticorps tau/anti-phf et leurs utilisations
MA41451A (fr) 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
US10202444B2 (en) 2015-02-24 2019-02-12 Rpeptide, Llc Anti-tau antibodies
AR103713A1 (es) 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
NZ775762A (en) * 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
ES2809728T3 (es) 2015-06-24 2021-03-05 Hoffmann La Roche Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
JP6643364B2 (ja) 2015-06-25 2020-02-12 インスティテュート フォー マスキュロスケレタル サイエンス アンド エジュケイション，リミテッド 移植用の椎体間固定装置およびシステム
SG10202010735PA (en) 2015-07-06 2020-11-27 UCB Biopharma SRL Tau-binding antibodies
CA2991264C (fr) 2015-07-06 2023-10-10 Ucb Biopharma Sprl Anticorps se liant a tau
WO2017011556A1 (fr) 2015-07-13 2017-01-19 The General Hospital Corporation Espèces tau à poids moléculaire élevé phosphorylées rares qui sont impliquées dans l'absorption et la propagation neuronales et leurs applications
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US10988528B2 (en) 2015-08-13 2021-04-27 New York University Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
PT3334761T (pt) 2015-08-13 2023-08-17 Univ New York Moléculas baseadas em anticorpo seletivo para o epítopo {p}ser404 da tau e os seus usos no diagnóstico e tratamento de tauopatias
JP7725185B2 (ja) 2015-10-06 2025-08-19 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
US20170138400A1 (en) 2015-11-12 2017-05-18 Schaeffler Technologies AG & Co. KG Bainite hardened stack bearing
WO2017100632A1 (fr) 2015-12-11 2017-06-15 Arizona Board Of Regents On Behalf Of Arizona State University Variants tau associés à la maladie d'alzheimer et aux lésions cérébrales traumatiques chez l'humain utilisés en tant que biomarqueurs et leurs méthodes d'utilisation
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
EP3452507B1 (fr) 2016-05-02 2022-10-19 Prothena Biosciences Limited Immunothérapie anti-tau
WO2017194589A1 (fr) 2016-05-10 2017-11-16 Vib Vzw Inhibition du dysfonctionnement synaptique précoce à médiation par tau
JP7029415B2 (ja) 2016-07-12 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 過リン酸化タウに特異的な抗体およびその使用方法
US10570196B2 (en) 2016-07-20 2020-02-25 Anahit Ghochikyan Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
WO2018018031A1 (fr) 2016-07-22 2018-01-25 New York University Murine spécifique et anticorps monoclonaux humanisés détectant des changements de structure secondaire associés à une pathologie dans des protéines et des peptides
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
EP3509622A4 (fr) 2016-09-08 2020-06-17 Regenerative Research Foundation Polypeptides anti-tau bi-fonctionnels et leur utilisation
FR3058143B1 (fr) 2016-10-27 2021-03-12 Univ Grenoble Alpes Nanocorps anti-tau
WO2018085653A1 (fr) 2016-11-04 2018-05-11 The Regents Of The University Of California Compositions ciblant la protéine tau à triple répétition pour le traitement de troubles neurodégénératifs, et leurs procédés de fabrication et d'utilisation
US9914781B1 (en) * 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
EP3551220B1 (fr) 2016-12-07 2025-01-29 Genentech, Inc. Anticorps anti-tau et ses utilisation
EP3551655A2 (fr) 2016-12-07 2019-10-16 Genentech, Inc. Anticorps anti-tau et méthodes d'utilisation de ces derniers
US10995137B2 (en) 2017-01-04 2021-05-04 H. Lundbeck A/S Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
TWI771389B (zh) 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
CN117205311A (zh) 2017-03-28 2023-12-12 基因泰克公司 治疗神经退行性疾病的方法
EP3602046A1 (fr) 2017-03-28 2020-02-05 Janssen Vaccines & Prevention B.V. Procédés de détection de composés modulant l'agrégation de protéines tau
EP3601325B1 (fr) 2017-03-28 2023-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouvelles especes de tau
CA3056517A1 (fr) 2017-03-28 2018-10-04 Janssen Vaccines & Prevention B.V. Molecules de liaison se liant specifiquement a tau
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
EA202090063A1 (ru) 2017-06-16 2020-04-03 Бристоль-Мейерз Сквибб Компани Композиции и способы для лечения таупатий
US10662246B2 (en) 2017-07-10 2020-05-26 New York University Monoclonal antibody to treat alzheimer's disease, prion disease, frontotemporal dementias and traumatic brain injury/chronic traumatic encephalopathy
US20210154184A1 (en) 2017-07-12 2021-05-27 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation
BR112020001922A2 (pt) 2017-08-01 2020-08-04 Amgen Inc. sistemas e métodos para realização de um ensaio de glicanas em tempo real de uma amostra
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
WO2019094576A1 (fr) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anticorps bispécifiques bace-tau

Also Published As

Publication number Publication date
WO2018152359A1 (fr) 2018-08-23
IL268658A (en) 2019-10-31
KR20190134997A (ko) 2019-12-05
US20200216522A1 (en) 2020-07-09
CA3053379A1 (fr) 2018-08-23
SG11201907422RA (en) 2019-09-27
JP2020508054A (ja) 2020-03-19
CN110520440A (zh) 2019-11-29
EP3583123A1 (fr) 2019-12-25
MX2019009817A (es) 2019-11-21
US11370832B2 (en) 2022-06-28
BR112019017021A2 (pt) 2020-04-14
TW201843175A (zh) 2018-12-16
AU2018221049A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
FR24C1044I2 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
MA48595A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA44955A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
EP3630199A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630788A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630789A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
EP3510040A4 (fr) Inhibiteurs d'éctonucléotidase et leurs procédés d'utilisation
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
EP3472200A4 (fr) Anticorps anti-myostatine et leurs procédés d'utilisation
EP3383914A4 (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA42446A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3436476A4 (fr) Anticorps anti-ryk et leurs procédés d'utilisation
EP3383430A4 (fr) Anticorps et leurs méthodes d'utilisation
EP3435956A4 (fr) Compositions photo-stabilisées et leurs procédés d'utilisation
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
EP3436061A4 (fr) Compositions de conjugués saccharide-polypeptide polymérisables et leurs procédés d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation